RLS Global (OM:RLS) - Aktienkurs, Nachrichten und Analyse

RLS Aktienübersicht

RLS Global AB (publ), a medical technology company, develops and sells products for minimally invasive treatment in Sweden.

Über das Unternehmen

RLS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Belohnungen

Risikoanalyse

RLS Global AB (publ) Wettbewerber

Eevia Health Oyj

NGM:EEVIA

kr20.9m

Newbury Pharmaceuticals

OM:NEWBRY

kr78.1m

Double Bond Pharmaceutical International

NGM:DBP B

kr47.9m

CS Medica

NGM:CSMED

kr.43.7m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for RLS Global
Historical stock prices
Current Share Price	kr0.45
52 Week High	kr3.49
52 Week Low	kr0.21
Beta	0.57
1 Month Change	-26.16%
3 Month Change	-35.36%
1 Year Change	-84.18%
3 Year Change	-93.07%
5 Year Change	-93.59%
Change since IPO	-70.27%

Aktuelle Nachrichten und Updates

Recent updates

We're Not Very Worried About RLS Global's (STO:RLS) Cash Burn Rate

Jan 13

Aktionärsrenditen

	RLS	SE Pharmaceuticals	SE Markt
7D	-0.2%	-5.9%	-2.1%
1Y	-84.2%	76.4%	11.2%

Preisvolatilität

Is RLS's price volatile compared to industry and market?
RLS volatility
RLS Average Weekly Movement	18.5%
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	5.9%
10% most volatile stocks in SE Market	12.7%
10% least volatile stocks in SE Market	3.5%

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1996	9	Roland Frosing	rls.global

RLS Global AB (publ)'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von RLS Global im Vergleich zum Marktanteil des Unternehmens?
RLS grundlegende Statistiken
Marktanteil	kr35.62m
Gewinn(TTM)	-kr28.81m
Umsatz(TTM)	kr1.08m

33.1x

Kurs-Umsatz-Verhältnis

-1.2x

Kurs-Gewinn-Verhältnis

Ist RLS zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
RLS Gewinn- und Verlustrechnung (TTM)
Einnahmen	kr1.08m
Kosten der Einnahmen	kr5.10m
Bruttogewinn	-kr4.02m
Sonstige Ausgaben	kr24.78m
Umsatz	-kr28.81m

Zuletzt gemeldete Gewinne

Jun 30, 2023

Datum des nächsten Gewinnberichts

Nov 23, 2023

Gewinn per Aktie (EPS)	-0.36
Bruttomarge	-374.07%
Nettogewinnspanne	-2,677.32%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich RLS auf lange Sicht entwickelt?

Historische Performance und Vergleiche

RLS Aktienübersicht

Belohnungen

Risikoanalyse

RLS Global AB (publ) Wettbewerber

NGM:EEVIA

kr20.9m

OM:NEWBRY

kr78.1m

NGM:DBP B

kr47.9m

NGM:CSMED

kr.43.7m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

RLS Global AB (publ) Announces First Patient Included in New Clinical Investigation on Pressure Ulcers

Less than half of directors are independent

Second quarter 2023 earnings released

RLS Global AB (publ) Announces Chief Financial Officer Changes

First quarter 2023 earnings released

Full year 2022 earnings released: kr0.35 loss per share (vs kr0.17 loss in FY 2021)

Recent updates

RLS Global AB (publ) Announces First Patient Included in New Clinical Investigation on Pressure Ulcers

Less than half of directors are independent

Second quarter 2023 earnings released

RLS Global AB (publ) Announces Chief Financial Officer Changes

First quarter 2023 earnings released

Full year 2022 earnings released: kr0.35 loss per share (vs kr0.17 loss in FY 2021)

Steve Krognes to Step Down as Chairman

Third quarter 2022 earnings released

Second quarter 2022 earnings released

RLS Global AB (publ) Announces Appointment of Björn Larsson as CEO, Effective October 1, 2022

RLS Global AB (publ) Introduces Chlorasolv in the Veterinary Care Segment in Scandinavia

First quarter 2022 earnings released: kr0.077 loss per share (vs kr0.094 loss in 1Q 2021)

RLS Global AB (publ) Announces Resignation of Karin Fischer as CEO

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

RLS Global AB (publ) to Report Q1, 2022 Results on May 11, 2022

Third quarter 2021 earnings released

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Second quarter 2021 earnings released: EPS kr0.13 (vs kr0.085 loss in 2Q 2020)

CEO & Chairman of the Management Board recently bought kr101k worth of stock

RLS Global AB (publ) Announces Outcome of the Complete Clinical Study ChloraSolv01

RLS Global AB Receives Regulatory Approval for ChloraSolv

First quarter 2021 earnings released

REGEDENT AG completed the acquisition of PeriSolv from RLS Global AB (publ) (OM:RLS).

New 90-day low: kr5.92

Full year 2020 earnings released: kr0.003 loss per share (vs kr0.44 loss in FY 2019)

New 90-day high: kr7.40

We're Not Very Worried About RLS Global's (STO:RLS) Cash Burn Rate

New 90-day low: kr5.96

CEO & Chairman of the Management Board recently bought kr131k worth of stock

RLS Global Presents Positive Results from the Chlorasolv01 Study at the Leading European Wound Management Conference, EWMA 2020

RLS Global Announces Acceptance of ChloraSolv by Region Skåne

New 90-day low: kr6.06

RLS Global AB Presents Data About Chlorasolv and its Rapid Response and High Efficacy on Biofilm

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

RLS Global AB (publ)'s Grundlagenzusammenfassung

33.1x

-1.2x

Erträge &amp; Einnahmen

Erträge & Einnahmen